Rebecca B Perkins1, Mengyun Lin, Sherrie F Wallington, Amresh Hanchate. 1. From the * Boston Medical Center, Boston University School of Medicine; †Veterans Affairs Boston Healthcare System, Boston University School of Medicine, Boston, MA; and ‡Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.
Abstract
BACKGROUND: The impact of fewer than 3 doses of human papillomavirus (HPV) vaccine on genital warts is uncertain. METHODS: Using the Truven Health Analytics Marketscan administrative database, we compared rates of genital warts among women receiving 0, 1, 2, or 3 doses of HPV vaccine. Females aged 9 to 18 years on January 1, 2007, who were continuously enrolled in the database through December 31, 2013, were included. Patients were assigned an HPV dose state (0, 1, 2, or 3) based on the last recorded dose. The exposure period began on January 1, 2007, or the date of the final HPV dose, and lasted until the first diagnosis of genital warts or December 31, 2013. Multivariable Poisson regression was performed to determine the risk of genital warts associated with vaccine doses. RESULTS: Among 387,906 subjects, mean age and exposure period were 14.73 and 5.64 years, respectively. The proportions of doses received were: 52.1%, 7.8%, 9.4%, and 30.7% for 0, 1, 2, and 3 doses, respectively. The rate of genital warts was 1.97/1000 person-years. Receipt of 0 or 1 dose was associated with more genital warts than 3 doses. The effectiveness of 2 doses following current Centers for Disease Control and Prevention guidelines was similar to 3 doses. The risk of genital warts rose with age. CONCLUSIONS: Prevention of genital warts is higher with completion of 3 vaccine doses than with 1 dose, though 2-dose recommendations appear to provide similar protection. Prospective effectiveness studies of recommended 2-dose schedules against clinical endpoints including persistent infection, genital warts, and cervical dysplasia are necessary to ensure long-term protection of vaccinated cohorts.
BACKGROUND: The impact of fewer than 3 doses of human papillomavirus (HPV) vaccine on genital warts is uncertain. METHODS: Using the Truven Health Analytics Marketscan administrative database, we compared rates of genital warts among women receiving 0, 1, 2, or 3 doses of HPV vaccine. Females aged 9 to 18 years on January 1, 2007, who were continuously enrolled in the database through December 31, 2013, were included. Patients were assigned an HPV dose state (0, 1, 2, or 3) based on the last recorded dose. The exposure period began on January 1, 2007, or the date of the final HPV dose, and lasted until the first diagnosis of genital warts or December 31, 2013. Multivariable Poisson regression was performed to determine the risk of genital warts associated with vaccine doses. RESULTS: Among 387,906 subjects, mean age and exposure period were 14.73 and 5.64 years, respectively. The proportions of doses received were: 52.1%, 7.8%, 9.4%, and 30.7% for 0, 1, 2, and 3 doses, respectively. The rate of genital warts was 1.97/1000 person-years. Receipt of 0 or 1 dose was associated with more genital warts than 3 doses. The effectiveness of 2 doses following current Centers for Disease Control and Prevention guidelines was similar to 3 doses. The risk of genital warts rose with age. CONCLUSIONS: Prevention of genital warts is higher with completion of 3 vaccine doses than with 1 dose, though 2-dose recommendations appear to provide similar protection. Prospective effectiveness studies of recommended 2-dose schedules against clinical endpoints including persistent infection, genital warts, and cervical dysplasia are necessary to ensure long-term protection of vaccinated cohorts.
Authors: Julia M L Brotherton; Masha Fridman; Cathryn L May; Genevieve Chappell; A Marion Saville; Dorota M Gertig Journal: Lancet Date: 2011-06-18 Impact factor: 79.321
Authors: Robine Donken; Mirjam J Knol; Johannes A Bogaards; Fiona R M van der Klis; Chris J L M Meijer; Hester E de Melker Journal: J Infect Date: 2015-02-21 Impact factor: 6.072
Authors: Mel Krajden; Darrel Cook; Amanda Yu; Ron Chow; Wendy Mei; Shelly McNeil; Deborah Money; Marc Dionne; Karuna P Karunakaran; Joel M Palefsky; Simon Dobson; Gina Ogilvie; Martin Petric Journal: Clin Vaccine Immunol Date: 2011-01-19
Authors: Suzanne E Powell; Susan Hariri; Martin Steinau; Heidi M Bauer; Nancy M Bennett; Karen C Bloch; Linda M Niccolai; Sean Schafer; Elizabeth R Unger; Lauri E Markowitz Journal: Vaccine Date: 2012-11-06 Impact factor: 3.641
Authors: Robine Donken; Tessa M Schurink-Van't Klooster; Rutger M Schepp; Fiona R M van der Klis; Mirjam J Knol; Chris J L M Meijer; Hester E de Melker Journal: J Infect Dis Date: 2017-02-01 Impact factor: 5.226
Authors: Jennifer C Spencer; Noel T Brewer; Justin G Trogdon; Morris Weinberger; Tamera Coyne-Beasley; Stephanie B Wheeler Journal: Pediatrics Date: 2020-11-16 Impact factor: 7.124